Manufacturing

Feliza Mirasol is the science editor for 

Articles

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

Olon Makes Headway into ADCs Market with New Manufacturing Facility in Italy

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

Markus Hörburger is product and service manager Secondary Packaging & Device Assembly at Vetter.

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

Converting Injectable Therapies to Combination Drug-Device Products

The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.

Owen Mumford and Stevanato Group Collaborate on Auto-Injector

Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.

Piramal Pharma Solutions Expands and Upgrades UK Manufacturing Facilities

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery. 

Considerations for DPIs and MDIs in Inhalation Drug Delivery

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Trends affecting primary pharmaceutical packaging include the shift to more complex drug-device combination products.

Primary Packaging for Combination Products

The contraceptive is expected to receive new chemical entity designation from FDA, giving it patent protection beyond 2030. It will be launched in early 2021, pending FDA approval. 

Mayne Enters 20-Year Agreement with Mithra for Oral Contraceptive Commercialization

The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.

Piramal Pharma Solutions Invests $10 million to Expand HPAPI Capability

A simple, one-part DPI aims to make inhalation drug treatment more accessible and affordable.

Manufacturing, Combination Drugs